Glaucoma News

Investigators found that a thin cornea and low corneal hysteresis have high significance in understanding which patients are at greater risk of glaucoma progression even with well-controlled IOP, according to a recently published study.

Fluctuating IOP was a significant and independent predictor for subsequent visual field deterioration in patients with primary angle closure glaucoma, according to findings published in the British Journal of Ophthalmology.

ORLANDO, Fla. – Researchers determined that minimum rim width measures on OCT can vary significantly from one 12-hour period to the next, so the test should be conducted at the same time of day to optimize repeatability, they said

ORLANDO, Fla. – Routine use of 10-2 visual field testing in early glaucoma was found to provide little clinical value to complement serial 24-2 testing, which is already considered standard of care, researchers reported here at the American Academy of Optometry meeting.

Allergan is voluntarily recalling certain lots of the Xen 45 glaucoma drainage device after a small number of units in an unreleased lot of the product were observed to have trace amounts of polishing compounds, according to a news release posted on the American Society of Cataract and Refractive Surgery website.

ORLANDO, Fla. – Optometrists should know the available options for minimally invasive glaucoma surgery and their mechanisms of action, but they should not recommend a specific procedure to a patient when making a surgical referral, Constance O. Okeke, MD, MSCE, said here at the Optometric Glaucoma Society meeting, held prior to the American Academy of Optometry meeting.

ORLANDO, Fla. – Nitric oxide signaling biomarkers contribute to glaucoma by causing increased IOP and vascular insufficiency, Louis R. Pasquale, MD, FARVO, hypothesized here at the Optometric Glaucoma Society meeting, held prior to the American Academy of Optometry meeting.

SAN FRANCISCO — A study showed Bimatoprost sustained-release implant was noninferior to timolol and may potentially provide sustained IOP control for patients with open-angle glaucoma or ocular hypertension, according to a speaker here.

SAN FRANCISCO — At the American Academy of Ophthalmology annual meeting, E. Randy Craven, MD, discusses a study showing the long-term IOP-lowering effect of the Bimatoprost SR implant from Allergan.

Glaukos has completed patient enrollment in an FDA investigational device exemption trial for the iStent infinite trabecular micro-bypass system.